by Jenny Berrío  , Weiwen Wang  and Bart A. Ellenbroek

Received: 22 February 2019;  Published: 14 March 2017;  doi: 10.21926/obm.neurobiol.1701001

Antipsychotics have been a pillar in the treatment of schizophrenia since their introduction more than 60 years ago. Their variety in structures and receptor binding properties confers on them a complex clinical profile of effectiveness and risk of adverse side-effects. Although antipsychotics are best known for their therapeutic effects in schizophrenia, these are limited to the positive symptoms, with much less influence on negative symptoms or cognitive deficits. Moreover, although the newer (so-called second-ge [...]